TY - JOUR
T1 - Changes in 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D are associated with maturation of regulatory T lymphocytes in patients with chronic pancreatitis
T2 - a randomized controlled trial
AU - Bang, Ulrich Christian
AU - Brandt, Lea
AU - Benfield, Thomas
AU - Jensen, Jens-Erik Beck
PY - 2012/11
Y1 - 2012/11
N2 - OBJECTIVES: We studied the impact of changes in 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)2D) on regulatory T lymphocytes (Tregs) in patients with chronic pancreatitis (CP) and fat malabsorption in a prospective clinical trial. METHODS: The patients were randomized to 1 of 3 treatments during 10 weeks: weekly UV-B in a tanning bed (group A), 1520-IU/d vitamin D supplement (group B), or placebo (group C). A placebo tanning bed was used in groups B and C. We determined the levels of CD4 Tregs (CD3CD4CD25CD127lowFoxP3) and CD8 Tregs (CD3CD8CD25CD127lowFoxP3), together with 25OHD and 1,25(OH)2D. For baseline comparisons, we included 8 healthy individuals. Of the 30 included patients, 27 (group A, 7 patients; group B, 9 patients; and group C, 11 patients) completed the protocol. RESULTS: The baseline levels of CD4 Tregs relative to total CD4 count were higher in 22 patients with CP compared with healthy controls (2.8% vs 1.9%, P < 0.05) and were comparable for CD8+ Tregs (0.13% vs 0.05%, P = 0.3). Increases in levels of CD4 Tregs correlated to changes in 1,25(OH)2D (2% per 100 pmol/L, P = 0.002) and 25OHD (3% per 100 nmol/L, P = 0.01). CONCLUSIONS: Patients with CP have elevated relative levels of CD4 Tregs. Increases in 25OHD and 1,25(OH)2D were both related with increases in levels of Tregs.
AB - OBJECTIVES: We studied the impact of changes in 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)2D) on regulatory T lymphocytes (Tregs) in patients with chronic pancreatitis (CP) and fat malabsorption in a prospective clinical trial. METHODS: The patients were randomized to 1 of 3 treatments during 10 weeks: weekly UV-B in a tanning bed (group A), 1520-IU/d vitamin D supplement (group B), or placebo (group C). A placebo tanning bed was used in groups B and C. We determined the levels of CD4 Tregs (CD3CD4CD25CD127lowFoxP3) and CD8 Tregs (CD3CD8CD25CD127lowFoxP3), together with 25OHD and 1,25(OH)2D. For baseline comparisons, we included 8 healthy individuals. Of the 30 included patients, 27 (group A, 7 patients; group B, 9 patients; and group C, 11 patients) completed the protocol. RESULTS: The baseline levels of CD4 Tregs relative to total CD4 count were higher in 22 patients with CP compared with healthy controls (2.8% vs 1.9%, P < 0.05) and were comparable for CD8+ Tregs (0.13% vs 0.05%, P = 0.3). Increases in levels of CD4 Tregs correlated to changes in 1,25(OH)2D (2% per 100 pmol/L, P = 0.002) and 25OHD (3% per 100 nmol/L, P = 0.01). CONCLUSIONS: Patients with CP have elevated relative levels of CD4 Tregs. Increases in 25OHD and 1,25(OH)2D were both related with increases in levels of Tregs.
KW - Aged
KW - Dietary Supplements
KW - Female
KW - Humans
KW - Lipid Metabolism
KW - Lymphocyte Activation/drug effects
KW - Malabsorption Syndromes/blood
KW - Male
KW - Middle Aged
KW - Pancreatitis, Chronic/blood
KW - T-Lymphocytes, Regulatory/drug effects
KW - Ultraviolet Therapy
KW - Vitamin D/administration & dosage
U2 - 10.1097/MPA.0b013e31824da377
DO - 10.1097/MPA.0b013e31824da377
M3 - Journal article
C2 - 22695134
SN - 0885-3177
VL - 41
SP - 1213
EP - 1218
JO - Pancreas
JF - Pancreas
IS - 8
ER -